Locana, Fueled With $55M, Looks to Develop Fixes for Faulty RNA

Editing human DNA has entered the public consciousness in a big way in recent years with its increasing use in laboratories?and, in recent news that shocked the scientific community, in embryos?of tools such as CRISPR-Cas9. Locana, a gene therapy biotech in San Diego, is taking what it describes as a ?parallel path? to developing therapeutics [?]